October 2, 2018 06:58 AM EDT

J&J shrugs off deals with Aduro that were worth up to $1.2B. Setback forces shift to Novartis alliance now

John Carroll

Editor & Founder

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

HHS says it's pulled Covid shot guidance for healthy kids. The CDC vaccine schedule shows otherwise

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

Lilly to buy non-opioid pain biotech SiteOne for up to $1B

Vertex touts promising first few months of launch for non-opioid pain drug Journavx

Vertex's next challenge for pain pill? Cracking a market dominated by cheap opioids

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation